AbbVie
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio
AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech
AbbVie’s Epkinly Enters Follicular Lymphoma Market, Competing with Roche’s Lunsumio
Epkinly, Lunsumio, follicular lymphoma, bispecific antibodies, AbbVie, Roche, FDA approval, cancer treatment
AbbVie’s Duopa Successor in Parkinson’s Rejected Again Due to Third-Party Manufacturer Issues
AbbVie, Duopa, Parkinson’s disease, FDA rejection, third-party manufacturer, ABBV-951, carbidopa, levodopa, subcutaneous pump device
AbbVie’s Parkinson’s Disease Therapy Rejected by FDA Due to Third-Party Manufacturer Issues
AbbVie, Parkinson’s disease, FDA, ABBV-951, foscarbidopa, foslevodopa, third-party manufacturer, regulatory issues
AbbVie’s Skyrizi Secures Key FDA Approval for Ulcerative Colitis Treatment
Skyrizi, AbbVie, FDA approval, ulcerative colitis, inflammatory bowel disease, IL-23 inhibitor, Crohn’s disease
Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar
Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials
Top 10 Pharmaceutical Drug Ad Spenders: A Review of the Latest Rankings
pharmaceutical drug ad spenders, top 10, AbbVie, Skyrizi, Rexulti, Dupixent, Rinvoq, Vraylar, Sotyktu, Jardiance, Ozempic, Caplyta, Opdivo
AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success
AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere